Journal of Hepatocellular Carcinoma
Volume 10, 2023 - Issue
ORIGINAL RESEARCH
Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
Xiujuan Chang1 Department of Liver Disease Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, People’s Republic of China
https://orcid.org/0000-0002-4961-8560View further author information
https://orcid.org/0000-0002-4961-8560View further author information, Shumin Yu2 302 Clinical Medical School Peking University, Beijing, 100039, People’s Republic of Chinahttps://orcid.org/0009-0004-5137-8502View further author information
https://orcid.org/0009-0004-5137-8502View further author information, , Wei Zhang1 Department of Liver Disease Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, People’s Republic of Chinahttps://orcid.org/0009-0009-3307-7905View further author information
https://orcid.org/0009-0009-3307-7905View further author information, Huifang Kong1 Department of Liver Disease Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, People’s Republic of Chinahttps://orcid.org/0009-0006-7619-7980View further author information
https://orcid.org/0009-0006-7619-7980View further author information, Jiagan Huang1 Department of Liver Disease Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, People’s Republic of Chinahttps://orcid.org/0009-0004-7234-0407View further author information
https://orcid.org/0009-0004-7234-0407View further author information, Guojie Zhang1 Department of Liver Disease Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, People’s Republic of Chinahttps://orcid.org/0009-0005-2160-932XView further author information
https://orcid.org/0009-0005-2160-932XView further author information, , Yueyue Gu1 Department of Liver Disease Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, People’s Republic of China;3 The Fifth School of Clinical Medicine, Anhui Medical University, Hefei, Anhui Province, 230032, People’s Republic of Chinahttps://orcid.org/0009-0002-3320-6964View further author information
https://orcid.org/0009-0002-3320-6964View further author information, Yan Chen1 Department of Liver Disease Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, People’s Republic of Chinahttps://orcid.org/0000-0001-6706-6301View further author information
https://orcid.org/0000-0001-6706-6301View further author information, Bin Yang1 Department of Liver Disease Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, People’s Republic of Chinahttps://orcid.org/0009-0006-8471-735XView further author information
https://orcid.org/0009-0006-8471-735XView further author information, Jingping Liu4 Oncology Department, Electric Power Hospital of Beijing, Beijing, 100073, People’s Republic of Chinahttps://orcid.org/0009-0003-6853-0892View further author information
https://orcid.org/0009-0003-6853-0892View further author information & Zhen Zeng1 Department of Liver Disease Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, 100039, People’s Republic of China;2 302 Clinical Medical School Peking University, Beijing, 100039, People’s Republic of China;3 The Fifth School of Clinical Medicine, Anhui Medical University, Hefei, Anhui Province, 230032, People’s Republic of ChinaCorrespondence[email protected]
https://orcid.org/0000-0002-1574-7196View further author information
https://orcid.org/0000-0002-1574-7196View further author information show all